Similar articles

• [Antiandrogen withdrawal syndrome].

  Akimoto S. Akimoto S. Nihon Rinsho. 1998 Aug;56(8):2135-9. Nihon Rinsho. 1998. PMID: 9750522 Review. Japanese.
• Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

  Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Hara T, et al. Cancer Res. 2003 Jan 1;63(1):149-53. Cancer Res. 2003. PMID: 12517791
• Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

  Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Suzuki H, et al. J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635218
• Molecular basis for the antiandrogen withdrawal syndrome.

  Miyamoto H, Rahman MM, Chang C. Miyamoto H, et al. J Cell Biochem. 2004 Jan 1;91(1):3-12. doi: 10.1002/jcb.10757. J Cell Biochem. 2004. PMID: 14689576 Review.
• Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.

  Longmore L, Foley JP, Rozanski TA, Higgins B, Thompson IM. Longmore L, et al. South Med J. 1998 Jun;91(6):573-5. doi: 10.1097/00007611-199806000-00013. South Med J. 1998. PMID: 9634122